MeSH term
Frequency | Condition_Probility | Animals | 25 | 0.0 |
Cell Line | 13 | 0.0 |
Hamsters | 3 | 0.0 |
Humans | 88 | 0.0 |
In Vitro | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
*Membrane Glycoproteins | 12 | 1.0 |
Research Support, Non-U.S. Gov't | 60 | 0.0 |
Base Sequence | 15 | 0.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Comparative Study | 13 | 0.0 |
Interferon Type II/pharmacology | 4 | 0.0 |
Interleukin-4 | 2 | 2.0 |
Molecular Sequence Data | 20 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Acute Disease | 2 | 0.0 |
Antigens, CD/analysis | 8 | 0.0 |
Antigens, Neoplasm/analysis | 5 | 1.0 |
Burkitt Lymphoma/immunology | 2 | 11.0 |
Flow Cytometry | 12 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
Amino Acid Sequence | 19 | 0.0 |
Antibodies, Monoclonal | 8 | 0.0 |
*Antigens, Neoplasm | 8 | 4.0 |
B-Lymphocytes/immunology | 5 | 0.0 |
Mice | 14 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
B-Lymphocytes/*immunology | 11 | 1.0 |
*Lymphocyte Depletion | 2 | 2.0 |
Lymphoma, B-Cell/*immunology | 3 | 7.0 |
Treatment Outcome | 2 | 0.0 |
Antigens, CD/*physiology | 2 | 0.0 |
Cell Communication | 3 | 1.0 |
Adult | 12 | 0.0 |
Female | 14 | 0.0 |
Male | 12 | 0.0 |
Middle Aged | 13 | 0.0 |
Antigens, CD/*metabolism | 2 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Antibodies, Monoclonal/immunology | 5 | 0.0 |
Antigens, CD/immunology/*metabolism | 3 | 6.0 |
Cell Adhesion | 2 | 0.0 |
Epitopes/immunology | 3 | 0.0 |
Integrin alpha3beta1 | 2 | 6.0 |
Integrins/*metabolism | 2 | 1.0 |
*Membrane Proteins | 6 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Molecular Weight | 3 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Cell Separation | 2 | 0.0 |
Signal Transduction/*immunology | 3 | 0.0 |
Gene Expression | 3 | 0.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Antigens, CD/immunology/metabolism | 2 | 3.0 |
B-Lymphocytes/*physiology | 2 | 1.0 |
*Signal Transduction | 2 | 0.0 |
Immunoenzyme Techniques | 7 | 0.0 |
Antigens, CD/*immunology | 2 | 0.0 |
Intercellular Adhesion Molecule-1/immunology | 2 | 4.0 |
Leukocytes/*immunology | 2 | 1.0 |
Platelet Membrane Glycoproteins/immunology | 2 | 11.0 |
*Multigene Family | 2 | 0.0 |
Aged | 6 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Bone Marrow/pathology | 2 | 0.0 |
Gene Rearrangement, B-Lymphocyte | 2 | 3.0 |
Immunophenotyping | 7 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Cell Division/immunology | 2 | 0.0 |
B-Lymphocytes/*chemistry | 2 | 9.0 |
Models, Biological | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
*Proto-Oncogene Proteins | 7 | 0.0 |
Antigens, CD/*genetics | 5 | 1.0 |
Blotting, Northern | 4 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Glycoproteins/*genetics | 3 | 1.0 |
Rats | 4 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Antigens, CD/immunology | 3 | 0.0 |
Antigens, Neoplasm/immunology | 4 | 3.0 |
B-Lymphocytes/immunology/*pathology | 2 | 7.0 |
Bone Marrow Cells | 3 | 0.0 |
Cattle | 3 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Antigens, CD19 | 3 | 1.0 |
Mutation | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Phenotype | 10 | 0.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Interleukin-4/pharmacology | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 6 | 3.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 7 | 0.0 |
Antigens, CD/*analysis | 7 | 0.0 |
B-Lymphocyte Subsets/*immunology | 2 | 2.0 |
Immunoglobulins, kappa-Chain/*analysis | 2 | 22.0 |
Leukemia, B-Cell, Chronic/*immunology | 2 | 4.0 |
Multiple Myeloma/*immunology | 3 | 8.0 |
Multigene Family | 2 | 0.0 |
Peptide Mapping | 2 | 0.0 |
Antigens, Surface/*analysis/genetics/immunology | 2 | 100.0 |
Lymphocyte Activation | 5 | 0.0 |
Macrophages/immunology | 2 | 0.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
Blotting, Western | 2 | 0.0 |
English Abstract | 2 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Antigens, Differentiation/analysis | 3 | 0.0 |
Antigens, Surface/analysis | 3 | 0.0 |
HLA-DR Antigens/analysis | 3 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics | 3 | 5.0 |
Glycosylation | 2 | 0.0 |
Antigens, Differentiation/*genetics | 3 | 2.0 |
Transfection | 4 | 0.0 |
Gene Library | 2 | 0.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Herpesvirus 4, Human | 2 | 1.0 |
DNA/isolation & purification | 2 | 1.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Fluorescent Antibody Technique | 9 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Antibodies, Monoclonal/*diagnostic use | 5 | 2.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Tonsil/immunology | 2 | 3.0 |
Antigens, CD40 | 2 | 3.0 |
Antigens, Surface/*analysis | 2 | 1.0 |
*Bone Marrow Cells | 2 | 0.0 |
Intercellular Adhesion Molecule-1 | 2 | 0.0 |
*Antigens, CD | 3 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 3 | 5.0 |
Blotting, Southern | 3 | 0.0 |
Restriction Mapping | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
Immunoglobulin M/metabolism | 2 | 2.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Signal Transduction/immunology | 2 | 0.0 |
Gene Rearrangement, T-Lymphocyte | 2 | 1.0 |
Genotype | 3 | 0.0 |
Adolescent | 5 | 0.0 |
Child | 3 | 0.0 |
Infant | 2 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Remission Induction | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Antibody Affinity | 2 | 1.0 |
Binding Sites, Antibody | 2 | 0.0 |
Immunoglobulins/*biosynthesis | 2 | 4.0 |
Leukocyte Count | 3 | 0.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Cytoplasm/immunology | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 2 | 0.0 |
Magnetics | 2 | 2.0 |
